Molecularly targeted therapy and immunotherapies have improved the care of patients with cancers. These successes have rallied calls to replace chemotherapy. Yet, even in this era of precision medicine and exciting advances, drug resistance remains an important obstacle for cancer treatment. Systematic therapies are gradually becoming mainstay of treatment for individuals whose cancers with oncogenic drivers have acquired resistance to chemotherapy agents. In the setting of locoregional disease, systemic therapies that include molecularly targeted agents and immune checkpoint inhibitors are the only therapies thus far proven to enhance curability when combined with surgery or radiation. In the metastatic setting, systemic therapy can improve the length and quality of life in many patients.
Molecularly targeted drugs and immune checkpoint inhibitors showed significant therapeutic effects on tumors. Molecularly targeted drugs also have the potential to modulate the immune system to enhance the effectiveness of immune checkpoint inhibitors, and vice versa. Previously, there are very limited treatment options for inoperable advanced solid tumors. Systemic therapy will change this situation and lead to better therapeutic outcomes. In this context, systemic therapy should be framed as a critical component of the armamentarium available for optimizing cancer care. We will discuss the role of targeted drug agents and immune checkpoint inhibitors in current cancer therapies, as well as opportunities for future integration in combinations in systemic therapy.
We welcome research submissions on the systemic therapy of solid tumors. The scope of researches we are looking forward to are as follows (not limited to):
• Molecular targeted drugs against chemotherapy resistance of tumor
• Immunosuppression of chemotherapy drug resistance in tumor
• Immune checkpoint inhibitors improve the prognosis of patients with targeted drug resistance
• Reasonable and efficient systematic treatment scheme design
• The design of novel molecular targeted drugs or immunotherapy drugs and their efficacy verification in cancer
Molecularly targeted therapy and immunotherapies have improved the care of patients with cancers. These successes have rallied calls to replace chemotherapy. Yet, even in this era of precision medicine and exciting advances, drug resistance remains an important obstacle for cancer treatment. Systematic therapies are gradually becoming mainstay of treatment for individuals whose cancers with oncogenic drivers have acquired resistance to chemotherapy agents. In the setting of locoregional disease, systemic therapies that include molecularly targeted agents and immune checkpoint inhibitors are the only therapies thus far proven to enhance curability when combined with surgery or radiation. In the metastatic setting, systemic therapy can improve the length and quality of life in many patients.
Molecularly targeted drugs and immune checkpoint inhibitors showed significant therapeutic effects on tumors. Molecularly targeted drugs also have the potential to modulate the immune system to enhance the effectiveness of immune checkpoint inhibitors, and vice versa. Previously, there are very limited treatment options for inoperable advanced solid tumors. Systemic therapy will change this situation and lead to better therapeutic outcomes. In this context, systemic therapy should be framed as a critical component of the armamentarium available for optimizing cancer care. We will discuss the role of targeted drug agents and immune checkpoint inhibitors in current cancer therapies, as well as opportunities for future integration in combinations in systemic therapy.
We welcome research submissions on the systemic therapy of solid tumors. The scope of researches we are looking forward to are as follows (not limited to):
• Molecular targeted drugs against chemotherapy resistance of tumor
• Immunosuppression of chemotherapy drug resistance in tumor
• Immune checkpoint inhibitors improve the prognosis of patients with targeted drug resistance
• Reasonable and efficient systematic treatment scheme design
• The design of novel molecular targeted drugs or immunotherapy drugs and their efficacy verification in cancer